3 results match your criteria: "1 University of Florida Colleges of Pharmacy and Medicine[Affiliation]"
Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
Ann Pharmacother
September 2019
2 University of Florida College of Pharmacy, Gainesville, FL, USA.
To review the pharmacology, efficacy, and safety of the calcitonin gene-related peptide (CGRP) inhibitor erenumab for migraine preventive therapy. A MEDLINE/PubMed search (January 2000 to January 2019) was conducted using the keywords , and . Additional articles were identified by hand from references.
View Article and Find Full Text PDFAndexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.
Ann Pharmacother
September 2019
1 University of Florida Colleges of Pharmacy and Medicine, Gainesville, FL, USA.
The purpose of this article is to review the available clinical trial data for andexanet alfa and its role in clinical practice. A MEDLINE/PubMed search was conducted (January 2000 to January 2019) using the keyword for clinical trials. References of identified articles were searched by hand for additional citations.
View Article and Find Full Text PDFErtugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.
Ann Pharmacother
May 2019
1 University of Florida Colleges of Pharmacy and Medicine, Gainesville, FL, USA.
Objective: The purpose of this article is to review the pharmacological aspects of ertugliflozin and its clinical trials, which led to Food and Drug Administration (FDA) approval for the treatment of type 2 diabetes mellitus (T2DM).
Data Sources: A MEDLINE/PubMed (May 2013 to October 2018) search was conducted using the following keywords: ertugliflozin, sodium glucose co-transporter 2 inhibitor, SGLT2 inhibitor, type 2 diabetes mellitus, hyperglycemia. Study Selection and Data Extraction Quantify: We included English-language articles evaluating ertugliflozin pharmacology, pharmacokinetics, efficacy, and safety in humans for blood glucose reduction in human subjects.